Zantac Cancer Lawsuit Claims: Medical Risks, Legal Rights, and Ongoing MDL Litigation in 2026
Since the FDA requested the withdrawal of ranitidine (Zantac) from the market in 2020 due to unacceptable levels of the probable human carcinogen N‑nitrosodimethylamine (NDMA), our past records show that thousands of individuals have come forward seeking accountability for cancers linked to this widely used heartburn medication. Today, as the multidistrict litigation (MDL) continues to progress through federal court, we provide clear, actionable guidance for those who suspect their cancer may be tied to long-term Zantac use. This is not a historical review—this is a live legal and medical crisis that still demands attention from plaintiffs, their families, and the medical community.
NDMA Contamination: The Scientific Evidence That Drives the Zantac Litigation
Ranitidine, the active ingredient in Zantac and its generic versions, was found to degrade into NDMA under normal storage and use conditions. As evidence evolved, independent testing revealed that NDMA levels could spike far above the FDA’s acceptable daily intake limit of 96 nanograms. The International Agency for Research on Cancer (IARC) classifies NDMA as a Group 2A probable human carcinogen. Epidemiological studies have linked prolonged NDMA exposure to several malignancies, including bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, liver cancer, and pancreatic cancer. The mechanism is well understood: NDMA forms DNA adducts that lead to mutations in critical oncogenes and tumor suppressor genes, particularly in the liver and gastrointestinal tract.
“The evidence connecting Zantac to cancer is not just statistical—it is biologically plausible and supported by decades of research on NDMA’s carcinogenicity in animal and human studies.”
—Read our full medical and legal analysis at marylandlaw.org/zantac-cancer-lawsuit-claims.html
The FDA first issued a public alert in September 2019, and by April 2020 ordered the removal of all ranitidine products from the market. Since then, more than 2,000 cases have been consolidated into MDL 2924 in the Southern District of Florida before Judge Robin L. Rosenberg. Plaintiffs allege that manufacturers—including Sanofi, Boehringer Ingelheim, and generic drug makers—failed to warn about the instability of the drug and the resulting NDMA contamination.
Legal Options & MDL Status: Statute of Limitations, Mass Tort Structure, and Settlement Prospects
The Zantac litigation is structured as a mass tort, not a class action, meaning each plaintiff retains individual control over their claim but benefits from centralized discovery and bellwether trials. In 2022 and 2023, federal bellwether trials yielded mixed results, with one defense verdict and one mistrial. However, as of 2026, the MDL judge continues to manage a complex docket, and numerous state court cases are progressing in parallel. Critical deadlines for claimants differ by state because of distinct statute of limitations rules. In Maryland, personal injury claims generally must be filed within three years of diagnosis, while wrongful death claims have a shorter window. The clock is ticking for many potential claimants who were diagnosed before the recall.
| Cancer Type | Latency Period (years of Zantac use) | Reported in MDL 2924 (approx.) |
|---|---|---|
| Bladder cancer | 10–20 | ~30% |
| Colorectal cancer | 5–15 | ~15% |
| Esophageal cancer | 15–25 | ~10% |
| Gastric cancer | 10–20 | ~12% |
| Liver cancer | 15–30 | ~8% |
| Pancreatic cancer | 10–20 | ~10% |
Any adverse event reported to the FDA that matches one of these cancer types and occurred after regular use of Zantac may form the basis of a claim. Litigation funding and case evaluation are ongoing, and several pharmaceutical companies have already reserved billions of dollars for potential settlement payouts. However, no global master settlement agreement has been reached as of early 2026; the MDL’s bellwether process is still being evaluated, and some defendants continue to contest causation.
How to Protect Your Rights and Determine if You Qualify for Compensation
If you or a loved one used Zantac (prescription or over-the-counter) for at least six months and later received a cancer diagnosis, time is of the essence. We recommend the following steps:
- Gather medical records documenting both the cancer diagnosis and any prescriptions or purchase history of ranitidine products.
- Identify the specific manufacturer of the Zantac you used; check old pill bottles or pharmacy records.
- Contact a qualified mass tort attorney who can evaluate the strength of your claim, including whether your cancer type is among those most strongly linked to NDMA.
- File your claim before the statute of limitations expires in your state; failure to do so may bar you from any future compensation.
Our legal partners work on a contingency basis, meaning you pay nothing unless a settlement or verdict is obtained. We can connect you with experienced lawyers who are actively participating in MDL 2924 and state court litigations. The path to compensation covers medical expenses, lost wages, pain and suffering, and in some cases punitive damages. To learn if you qualify for a free case evaluation, contact our team today.
Disclaimer: This article does not constitute legal or medical advice. Consult with a licensed attorney and healthcare provider for personal guidance.